Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ACADEMIA
ACADEMIA
- Japan Study Finds No Evidence of Increased Cancer Risk for Sitagliptin
September 3, 2024
- A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
August 28, 2024
- As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
August 9, 2024
- Japan’s Antibiotic Use Up 22.3% in 2023 after COVID Restrictions Lifted
August 7, 2024
- NCC Out-Licenses UPenn-Partnered Cell Therapy to Spinout Company
July 12, 2024
- 8.5% of Long-COVID Patients Still Seriously Affected after 6 Months: Survey
July 4, 2024
- Academic Society Frets Availability of 1st-Gen Oral Cephems amid Choseido Halt
June 24, 2024
- MHLW-Funded Study Group Designing New Care Delivery Model for Alzheimer’s
June 14, 2024
- Leukemia Drug Slows ALS Progression in Japan Clinical Trial
June 13, 2024
- Akira Endo, Who Pioneered Discovery of Statins, Dies at 90
June 12, 2024
- Single-Injection Beyfortus Will Reduce Burdens on Parents and Children: Experts
June 10, 2024
- Researchers Crafting Japan’s 1st Guidelines for ALS Trials, Eye FY2026 Completion
May 14, 2024
- Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
May 8, 2024
- Lecanemab Combo Trial Launched in Japan for Familial Alzheimer’s
March 18, 2024
- Pediatric Specialist Pins Hope on Efficacy of Pfizer’s RSV Shot in Healthy Infants
March 12, 2024
- Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
March 8, 2024
- JSMO Panelists Urge Measures to Lure US Biotechs to Fight Drug Loss
February 27, 2024
- Pneumococcal Jabs Help Curb Pediatric Emergency Visits: Pediatrician
February 26, 2024
- KOL Highlights Need for Further RSV Epidemiological Research in Japan
February 15, 2024
- Drug Loss Is Intensifying for Rare Cancers amid Rise of Biotech Developers: JSMO Director
February 5, 2024
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…